HCAR2 and neoplasm: Mechanistically, butyrate boosts the tumor-killing capacity of CD8+ T cells and Claudin 18.2-targeting CAR-T cells through the GPR109A-homologous domain protein homologous box (HOPX) pathway, thereby restoring antitumor immunity and thus suppressing gastric tumorigenesis [67].